Skip to main content
Quest PharmaTech Inc. logo

Quest PharmaTech Inc. - Investor Relations & Filings

Listed IPO Jul 1997
Ticker · QPT ISIN · CA74836M1068 TSXV Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2024-05-29 Regulatory Filings
Country CA Canada
Listing TSXV QPT · 4 venues

Key figures FY2024

Period ended 2024-01-31 · CAD
Headline annual figures for Quest PharmaTech Inc., fiscal year 2024, reported in CAD, with the source filing for each figure.
Net Income CAD -3.02M per the Annual Report filed 2024-05-29
Total Assets CAD 24.48M per the Annual Report filed 2024-05-29
Total Equity CAD 23.15M per the Annual Report filed 2024-05-29
Cash from Ops CAD -342.42k per the Annual Report filed 2024-05-29

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Quest PharmaTech Inc.

https://questpharmatech.com/

Quest PharmaTech Inc. is a biopharmaceutical company focused on the discovery and development of novel therapeutics. The company's pipeline targets applications in cancer treatment, dermatology, and wound healing, utilizing both proprietary technologies, such as transdermal delivery systems, and strategic investments. A core proprietary asset is the antibody Mab AR 9.6, licensed for targeted cancer therapy against truncated O-glycan on MUC16. Quest also maintains significant ownership interests in associated entities, including OncoVent, and holds convertible bond interests in OncoQuest Pharmaceuticals, Inc. (OQP). These OQP bonds are planned to be exchanged into shares of Canaria Bio, a company developing immunotherapy assets, providing Quest with an expected ownership stake of approximately 23% in Canaria Bio upon conversion.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a 'Form 52-109FV1', which is a standard Canadian regulatory certification form for venture issuers. It is an officer certification (CEO) attesting to the accuracy of previously filed annual reports. Per the 'Certification Rule' provided in the instructions, documents that are primarily officer certifications or attestations must be classified as Regulatory Filings (RNS), even if they reference other report types like annual filings.
2024-05-29 English
Annual MD&A - English.pdf
Management Reports Classification · 100% confidence The document is a 'Management's Discussion & Analysis' (MD&A) for Quest PharmaTech Inc. for the fiscal year ended January 31, 2024. It provides a detailed narrative explanation of financial results, business operations, risks, and liquidity, which is the standard content for an MD&A report. While it references audited financial statements, the document itself is the management commentary component of the annual reporting package. According to the provided definitions, 'MDA' is the specific category for management's detailed explanation of financial results and business trends.
2024-05-29 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1, which is a regulatory filing required by the Alberta Securities Commission for reporting issuers to calculate and pay their annual participation fees. It includes a management certification by the CFO and market capitalization data used to determine the fee. As it is a regulatory compliance document and not a financial report, earnings release, or other specific category, it falls under the RNS (Regulatory Filings) category.
2024-05-29 English
Audited annual financial statements – English.pdf
Annual Report Classification · 95% confidence The document is a comprehensive set of audited consolidated financial statements for Quest PharmaTech Inc. for the fiscal years ended January 31, 2024 and 2023. It includes a Management's Responsibility Statement, an Independent Auditor's Report, and the primary financial statements (Statement of Financial Position, Statement of Loss, etc.). While it contains an audit report, the document as a whole is the complete annual financial reporting package, which aligns with the definition of an Annual Report (10-K). FY 2024
2024-05-29 English
52-109F2R - Certification of refiled interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a 'Form 52-109F2R', which is a regulatory certification form for refiled interim filings. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like interim filings), should be classified as Regulatory Filings (RNS). The document does not contain the actual financial statements or data, but rather serves as a legal attestation by the CFO.
2024-05-28 English
Interim MD&A (amended) - English.pdf
Management Reports Classification · 100% confidence The document is a 'Restated Management's Discussion & Analysis' (MD&A) for the nine months ended October 31, 2023. It provides a detailed narrative explanation of financial results, business operations, liquidity, and risk factors, which is the primary function of an MD&A report. While it mentions being a 'restated' version, it is a substantive financial management report rather than a simple regulatory notice or announcement. Therefore, it is classified as a Management Report (MDA).
2024-05-28 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.